RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity.
性状
Solid
IC50 & Target[1][2]
p38α
1 μM (IC50)
p38β
11 μM (IC50)
体外研究(In Vitro)
RWJ-67657 inhibits the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells with an IC50 of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B, with an IC50 value of 13 nM.
RWJ67657 (10 μM; 24 hours) decreases colony formation in MCF-7 cells.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay
Cell Line:
MCF-7 breast carcinoma cells
Concentration:
10 μM
Incubation Time:
24 hours
Result:
Decreased colony formation.
体内研究(In Vivo)
RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration.
RWJ-67657 (50 mg/kg; administered orally; once per day for 7 consecutive days) displays a potent anti-inflammatory effect. By both improving the functioning of endothelial progenitor cells (EPCs) and reducing inflammation, EPC transplantation plus RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis after diabetic stroke.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
The db/db mice (male, 8 weeks old) with EPCs
Dosage:
50 mg/kg
Administration:
Administered orally; once per day for 7 consecutive days
Result:
Increased angiogenesis and neurogenesis of diabetic mice after cotreatment with EPCs transplantation.